smoking cessation drugs_world market prospects 2013-2023

7/27/2019 Smoking Cessation Drugs_World Market Prospects 2013-2023

1/19

noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-chase and single copy is for personal use only.

Smoking Cessation Drugs:

World Market Prospects 2013-2023


2/19

www.visiongain.com

Contents

1.1 Smoking Cessation Drugs: World Market Overview

1.2 Aims and Format of the Report

1.3 Research and Analysis Methods

1.4 Scope of the Report

2.1 Tobacco- What is All the Fuss About?

2.1.1 How is Tobacco Consumed?

2.1.2 Tobacco Smoking is a Major Challenge for Healthcare Worldwide

2.2 Smoking Causes Many Health Disorders

2.3 Nicotine Addiction is at the Root of Smoking

2.4 Smoking Cessation

2.4.1 Why is it Difficult to Stop Smoking?

2.4.2 How Can Smokers Quit?

3.1 How Will the Smoking Cessation Market Develop Until 2023?

3.2 Smoking Cessation Drugs Market by Type of Sale

3.2.1 Over-the-Counter (OTC) Smoking Cessation Drugs, 2012

3.2.1.1 OTC Smoking Cessation Drugs: Forecast, 2013-2023

3.2.2 Prescription (Rx) Smoking Cessation Drugs, 2012

3.2.2.1 Prescription Smoking Cessation Drugs: Forecast, 2013-20233.3 Smoking Cessation Drugs by Mechanism of Action

3.3.1 Nicotine Replacement Therapy

3.3.1.1 Nicotine Replacement Therapy, 2012

3.3.1.2 Nicotine Replacement Therapy Forecast, 2013-2023

1. Executive Summary

2. Introduction to Smoking Cessation

3. World Smoking Cessation Drugs Market, 2013-2023


3/19

www.visiongain.com

Contents

3.3.2 Nicotine Receptor Partial Agonist Drugs

3.3.2.1 Nicotine Receptor Partial Agonist Drugs, 2012

3.3.2.2 Nicotine Receptor Partial Agonist Drugs Forecast, 2013-2023

3.3.3 Antidepressants

3.3.3.1 Antidepressants for Smoking Cessation, 2012

3.3.3.2 Antidepressants for Smoking Cessation: Forecast, 2013-2023

4.1 Major Geographical Markets for the Smoking Cessation Industry in 2012

4.2 The US is Still the Market Leader

4.2.1 Smoking Prevalence Declining in the US

4.2.2 Availability and Reimbursement of Smoking Cessation Aids in the US

4.2.3 US Smoking Cessation Market Revenue, 2012

4.2.4 US Smoking Cessation Market Forecast, 2013-2023

4.2.5 Scope for US Smoking Cessation Market Expansion

4.3 The Japanese Smoking Cessation Market has Potential to Expand in Revenues

4.3.1 Japan has a Less Developed Smoking Cessation Market

4.3.2 The Japanese Smoking Cessation Market, 2012

4.3.3 Japanese Smoking Cessation Market Forecast, 2013-2023

4.4 The EU-5 Smoking Cessation Drugs Market

4.4.1 The UK Smoking Cessation Market

4.4.1.1 Tobacco Use in the UK

4.4.1.2 The UK Pioneers Smoking Cessation Reimbursement and General Sales OTC Retailingof NRT

4.4.1.3 The UK has Strong Anti-Smoking Legislation

4.4.1.4 UK Smoking Cessation Market, 2012

4.4.1.5 UK Smoking Cessation Market Forecast, 2013-2023

4. Leading National Markets for Smoking Cessation Drugs to 2023


4/19

www.visiongain.com

Contents

4.4.2 The French Smoking Cessation Market

4.4.2.1 Tobacco Use in France is Still High

4.4.2.2 The French Smoking Cessation Market, 2012

4.4.2.3 French Smoking Cessation Market Forecast, 2013-2023

4.4.2.4 Factors Influencing the Development of the French Market

4.4.3 The Spanish Smoking Cessation Market

4.4.3.1 Tobacco Use in Spain is Low

4.4.3.2 The Spanish Smoking Cessation Market, 2012

4.4.3.3 The Spanish Smoking Cessation Market Forecast, 2013-2023

4.4.3.4 Spains Anti-smoking Laws are Very Robust

4.4.4 The Italian Smoking Cessation Market

4.4.4.1 Reducing Tobacco Use in Italy is a Government Priority

4.4.4.2 The Italian Smoking Cessation Market, 2012

4.4.4.3 The Italian Smoking Cessation Market Forecast, 2013-2023

4.4.4.4 Italy has a Decades-Long Commitment to Reducing Smoking

4.4.5 The German Smoking Cessation Market

4.4.5.1 Germany is a Smokers Citadel

4.4.5.2 The German Smoking Cessation Market, 2012

4.4.5.3 German Smoking Cessation Market Forecast, 2013-2023

4.4.5.4 Germany Has a Relaxed Attitude to Smoking

4.5 The BRIC Smoking Cessation Drugs Market is Untapped

4.5.1 The Brazilian Smoking Cessation Market

4.5.1.1 Tobacco Use in Brazil is Pervasive

4.5.1.2 The Brazilian Smoking Cessation Market, 20124.5.1.3 Brazilian Smoking Cessation Market Forecast, 2013-2023

4.5.1.4 Smoking Cessation Market Prospects in Brazil Look Bright

4.5.2 The Russian Smoking Cessation Market

4.5.2.1 Tobacco Use in Russia Forms a Serious Problem


5/19

www.visiongain.com

Contents

4.5.2.2 The Russian Smoking Cessation Market, 2012

4.5.2.3 Russian Smoking Cessation Market Forecast, 2013-2023

4.5.2.4 The Russian Government has started to Take Positive Steps

4.5.3 The Indian Smoking Cessation Market: Vast Possibilities

4.5.3.1 Indias Attitudes to Tobacco

4.5.3.2 The Indian Smoking Cessation Market, 2012

4.5.3.3 Indian Smoking Cessation Market Forecast, 2013-2023

4.5.3.4 Indian Smoking Cessation Market Still in its Infancy

4.5.3.5 Prospects for Growth of the Indian Smoking Cessation Market

4.5.4 The Chinese Smoking Cessation Market

4.5.4.1 Tobacco use in China is Unprecedented

4.5.4.2 The Chinese Smoking Cessation Market, 2012

4.5.4.3 Chinese Smoking Cessation Market Forecast, 2013-2023

4.5.4.4 The Chinese Smoking Cessation Market is Under Developed

4.5.4.5 Chinas Economic Progress Could be Hindered by Tobacco Use

5.1 The Top 5 Brands Claimed Most of the Market in 2012

5.2 Nicotine Replacement Therapy is a Main Component of the Market

5.2.1 NiQuitin/Nicabate/NicoDerm CQ (GSK)

5.2.2 Nicorette (Johnson & Johnson/GSK)

5.2.3 Nicotinell (Novartis)

5.2.4 Other NRT Products

5.3 Champix/Chantix (Varenicline, Pfizer)

5.3.1 Champix/Chantix Sales Performance, 2012-2023

5.3.2 Champix/Chantix May Help in Treating Other Addictions

5.4 Zyban (Bupropion, GSK)

5. Leading Smoking Cessation Products: Outlook to 2023


6/19

www.visiongain.com

Contents

5.4.1 Zyban Sales Forecast, 2012-2023

5.5 Tabex One to Watch Out For

5.6 Other Smoking Cessation Aids

5.6.1 Smokeless Tobacco

5.6.1.1 E-Cigarettes

5.6.1.2 Snus/Snuff

5.6.1.3 Gutkhas

5.6.2 CigRx Dietary Supplement

5.6.3 Dissolvable Tobacco

5.6.4 Behavioural Therapy

6.1 Nicotine Vaccines: Hype or Hope?

6.1.1 TA-Nic (Celtic Pharma)

6.1.2 Niccine (Independent Pharmaceutica AB)

6.1.3 SEL-068 (Selecta Biosciences)6.2 Monoamine Oxidase Inhibitors

6.3 Cannabinoid Receptor-1 Antagonists

6.4 Dopamine D3 Antagonists

6.5 Opiate Antagonists

6.6 ARD-1600 (Aradigm)

6.7 EMB-001(Embera NeuroTherapeutics)

6.8 Meclizine (Duke University/Philip Morris Products)

6.9 Other Smoking Cessation Aids Under Development

6.9.1 X22TM

(22nd

Century Group)

6.9.2 Other Developments

6. Smoking Cessation R&D Pipeline Analysis


7/19

www.visiongain.com

Contents

7.1 The Smoking Cessation Market was Dominated by Four Companies, But for How Long?

7.2 SWOT and STEP Analysis of the Smoking Cessation Market

7.2.1 Strengths of the Smoking Cessation Industry

7.2.1.1 Innovation in Smoking Cessation Therapies

7.2.1.2 Innovative Marketing

7.2.1.3 Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy

7.2.1.4 OTC Switching

7.2.1.5 Widespread Coverage of Smoking Cessation Products

7.2.2 Weaknesses of the Smoking Cessation Industry

7.2.2.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking

7.2.2.2 Currently-Marketed Smoking Cessation Therapies Relapse Rate

7.2.2.3 Concerns Regarding the Development of Addiction to NRTs

7.2.3 Opportunities for the Smoking Cessation Industry

7.2.3.1 Smoking is Prevalent Worldwide and Slowly Increasing

7.2.3.2 Countries with Untapped Smoking Cessation Market Potential7.2.3.3 Growth of Emerging-Economy Smoking Cessation Markets

7.2.3.4 Health Effects of Tobacco

7.2.3.5 Economic and Social Impact of Tobacco on Society

7.2.3.6 Framework Convention on Tobacco Control (FCTC)

7.2.3.7 Government-Sponsored Smoking Cessation Programmes

7.2.3.8 Increasing Tobacco Taxes

7.2.3.9 Smoking Bans

7.2.3.10 Warning Information on Tobacco Products

7.2.3.11 Bans on Tobacco Advertising, Promotion and Sponsorship

7.2.3.12 Upcoming Launch of Tabex

7.2.4 Threats to the Smoking Cessation Industry

7. Smoking Cessation Industry: Qualitative Analyses, 2013-2023


8/19

www.visiongain.com

Contents

7.2.4.1 Concern over Side-Effects of Smoking Cessation Drugs

7.2.4.2 Lack of Reimbursement for Smoking Cessation Therapies

7.2.4.3 Traditional Smokeless Tobacco

7.2.4.4 The E-Cigarette

8.1 Interview with Dr Vladimir Kosev, Director Strategic Business Development, Sopharma

8.1.1 On Sopharmas Geographical Focus

8.1.2 On the Availability of Tabex8.1.3 On the Efficacy of Tabex in Comparison to Other Products

8.1.4 On Any Other Points of Interest

8.2 Interview with Mr Rick Stewart, CEO, Extab Corporation

8.2.1 On Tabexs Release

8.2.2 On Tabex vs. Other Smoking Cessation Treatments

8.2.3 On the High Prices of Smoking Cessation Products Reducing Revenues in Poorer Nations

8.2.4 On the Future Direction of the Industry

8.2.5 On Any Other Points of Interest

8.3 Interview with Mr Trevor Van Meirlo, CEO, Evolution Health Systems

8.3.1 Unmet Needs

8.3.2 Major Areas of Focus

8.3.3 Smoking Cessation R&D Pipeline

8.3.4 Opportunities for Revenue Growth

8.3.5 Market Drivers

8.4 Interview with Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute

of Preventive Medicine, Barts and The London School of Medicine and Dentistry, University of

London

8.4.1 Unmet Needs

8. Research Interviews


9/19

www.visiongain.com

Contents

8.4.2 Major Areas of Focus and R&D Pipeline

8.4.3 Opportunities for Revenue Growth

8.4.4 Market Drivers

9.1 Smoking is the Main Cause of Preventable Deaths Worldwide

9.2 Smoking Cessation Medicines Have Promising Therapeutic and Commercial Potential from 2013

to 2023

9.3 World Smoking Cessation Market: Prospects to 2023

9.4 Market Drivers

9.5 Leading and Emerging Smoking Cessation Markets

9.6 Concluding Remarks

9. Conclusions of the Study


10/19

www.visiongain.com

Contents

Table 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023

Table 3.2 World Smoking Cessation Market Drivers and Restraints, 2012-2023

Table 3.3 Smoking Cessation Drug Market Forecast ($m) by Type of Sales, 2012-2023

Table 3.4 Over-The-Counter Smoking Cessation Market Forecast ($m), 2012-2023

Table 3.5 OTC Smoking Cessation Market Drivers and Restraints, 2012-2023

Table 3.6 Prescription (Rx) Smoking Cessation Market Forecast ($m), 2012-2023

Table 3.7 Prescription Smoking Cessation Drivers and Restraints, 2012-2023

Table 3.8 Smoking Cessation Market Forecasts by Drug Type ($m), 2012-2023

Table 3.9 Nicotine Replacement Therapy Market Forecast ($m), 2012-2023

Table 3.10 Nicotine Replacement Therapy Drivers and Restraints, 2012-2023

Table 3.11 NRPA Market Forecast ($m), 2012-2023

Table 3.12 NRPA Drivers and Restraints, 2012-2023

Table 3.13 Antidepressants Market Forecast ($m), 2012-2023

Table 3.14 Antidepressants Market Drivers and Restraints, 2012-2023

Table 4.1 Smoking Cessation Drugs Market Forecast ($m) by Leading Countries, 2012-2023

Table 4.2 Smoking Cessation Drugs Market Forecast ($m) & Market Shares (%) by Leading

Countries, 2012

Table 4.3 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023

Table 4.4 US Smoking Cessation Market Drivers and Restraints, 2012-2023

Table 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023

Table 4.6 Japanese Smoking Market Cessation Drugs Drivers and Restraints, 2012-2023

Table 4.7 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023Table 4.8 EU-5 Smoking Cessation Market Drivers and Restraints, 2012-2023

Table 4.9 UK Smoking Cessation Market Forecast ($m), 2012-2023

Table 4.10 French Smoking Cessation Market Forecast ($m), 2012-2023

Table 4.11 Spanish Smoking Cessation Market Forecast ($m), 2012-2023

List of Tables


11/19

www.visiongain.com

Contents

Table 4.12 Italian Smoking Cessation Market Forecast ($m), 2012-2023

Table 4.13 German Smoking Cessation Market Forecast ($m), 2012-2023

Table 4.14 BRIC Smoking Cessation Market Forecasts ($m), 2012-2023

Table 4.15 BRIC Smoking Cessation Drugs Drivers and Restraints, 2012-2023

Table 4.16 Brazilian Smoking Cessation Market Forecasts ($m), 2012-2023

Table 4.17 Russian Smoking Cessation Market Forecasts ($m), 2012-2023

Table 4.18 Indian Smoking Cessation Market Forecast ($m), 2012-2023

Table 4.19 Chinese Smoking Cessation Market Forecast ($m), 2012-2023

Table 5.1 Top 5 Smoking Cessation Drugs Sales ($m) and Market Shares (%), 2012

Table 5.2 Leading Smoking Cessation Brands: Sales Forecasts ($m), 2012-2023

Table 5.3 Nicotine Replacement Therapy Types, 2012

Table 5.4 NiQuitin /Nicabate/NicoDerm CQ NRT Brands, 2012

Table 5.5 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023

Table 5.6 NiQuitin/Nicabate/NicoDerm CQ Drivers and Restraints, 2012-2023

Table 5.7 Nicorette NRT Brands, 2012

Table 5.8 Nicorette Sales Forecast ($m), 2012-2023

Table 5.9 Nicorette Drivers and Restraints, 2012-2023

Table 5.10 Nicotinell Sales Forecast ($m), 2012-2023

Table 5.11 Nicotinell Drivers and Restraints, 2012-2023

Table 5.12 Champix/Chantix Sales Forecast ($m), 2012-2023

Table 5.13 Champix/Chantix Drivers and Restraints, 2012-2023

Table 5.14 Zyban Sales Forecast ($m), 2012-2023

Table 5.15 Zyban Drivers and Restraints 2012-2023

Table 5.16 Tabex Sales Forecast ($m), 2012-2023Table 5.17 Tabex Drivers and Restraints, 2012-2023

Table 6.1 Smoking Cessation R&D Pipeline: Some Leading Product Candidates, 2013

Table 6.2 Smoking Cessation R&D Pipeline: Apparent Disappointments


12/19

www.visiongain.com

Contents

Table 7.1 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and

Market Share (%), 2012

Table 7.2 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and

Market Share (%), 2023

Table 7.3 Other Companies Operating in the Smoking Cessation Industry

Table 7.4 SWOT Analysis of the Industry and Market, 2012-2023

Table 7.5 STEP Analysis of the Industry and Market, 2012-2023

Table 9.1 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by OTC and Rx,

2013, 2017 & 2023

Table 9.2 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Drug Type,

2013, 2017 & 2023

Table 9.3 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Leading

Countries, 2013, 2017 & 2023


13/19

www.visiongain.com

Contents

Figure 2.1 Smoking-Related Health Disorders

Figure 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023

Figure 3.2 Smoking Cessation Market Shares (%) by Type of Sale, 2012

Figure 3.3 OTC Smoking Cessation Drugs Market Forecast ($m), 2012-2023

Figure 3.4 Rx Smoking Cessation Market Forecast ($m), 2012-2023

Figure 3.5 Smoking Cessation Market Shares (%) by Drug Type, 2012

Figure 3.6 NRT Market Forecast ($m), 2012-2023Figure 3.7 NRPA Market Forecast ($m), 2012-2023

Figure 3.8 Antidepressants for Smoking Cessation: Market Forecast ($m), 2012-2023

Figure 4.1 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2012



Figure 4.4 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023

Figure 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023Figure 4.6 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023

Figure 4.7 UK Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.8 French Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.9 Spanish Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.10 Italian Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.11 German Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.12 BRIC Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.13 Brazilian Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.14 Russian Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.15 Indian Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.16 Chinese Smoking Cessation Market Forecast ($m), 2012-2023

List of Figures


14/19

www.visiongain.com

Contents

Figure 5.1 Top 5 Smoking Cessation Drugs: Market Shares (%), 2012

Figure 5.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023

Figure 5.3 Nicorette Sales Forecast ($m), 2012-2023

Figure 5.4 Nicotinell Sales Forecast ($m), 2012-2023

Figure 5.5 Champix/Chantix Sales Forecast ($m), 2012-2023

Figure 5.6 Zyban Sales Forecast ($m), 2012-2023

Figure 5.7 Tabex Sales Forecast ($m), 2012-2023

Figure 7.1 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2012

Figure 7.2 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2023

Figure 9.1 Smoking Cessation Drugs: World Market Revenue Forecast ($m), 2012-2023

Figure 9.2 Smoking Cessation Drug Market by Leading Countries: Market Shares (%), 2013, 2017 &

2023


15/19

www.visiongain.com

Contents

22nd

Century Group

Action on Smoking on Health (ASH)

Advent Life Sciences

Alkermes

American Heart Association (AHA)

American Lung Association (ALA)

Aradigm

Australian Therapeutic Goods Administration

BGP Group

Boots

Cochrane Collaboration

Cambrex

Campaign for Tobacco-Free Kids

Cancer Centre and Institute of Oncology

Ceejay Healthcare

Celtic Pharma

Centers for Disease Control and Prevention (CDC)

Cephalon

China National Tobacco Corporation

CN Creative

Cytos Biotechnology

Duke UniversityEmbera NeuroTherapeutics

European Medicines Agency (EMA)

Evolution Health Systems

Evotec

Organisations Mentioned


16/19

www.visiongain.com

Contents

Excelsa Pharma

Extab Corporation

Fertin Pharma A/S

Food and Drug Administration (US FDA)

GlaxoSmithKline (GSK)

Haihang Industry Company

Health Canada

Independent Pharmaceutica AB

Japanese Ministry of Health, Labour and Welfare (MHLW)

Japan Tobacco

Johnson & Johnson

Karolinska Institutet

LEO Pharma

LSU Health Sciences Center Shreveport

Mayo Clinic

Medicines and Healthcare Products Regulatory Agency (MHRA)

Nabi Biopharmaceuticals

National Cancer Institute (NCI)

National Health Service (UK NHS)

National Institute for Health and Clinical Excellence (UK NICE)

National Institute on Drug Abuse (NIDA)

Next Safety

Nicobrand

Niconovum ABNicoventures

Novartis

Nulife

Nu-Mark


17/19

www.visiongain.com

Contents

Perrigo

Pfizer

Philip Morris Products S.A

Queen Mary University of London

Revolymer

R.J. Reynolds Tobacco Company

Rock Creek Pharmaceuticals

Roche

Ruyan

Sanofi

Selecta Biosciences

Sopharma

Spanish Ministry of Health, Social Services and Equality

Star Scientific

Taj Pharmaceuticals

Target Corporation

Teva Pharmaceutical Industries

Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The

London School of Medicine and Dentistry

Tobacco Manufacturers Association

University College London (UCL)

UK Centre for Tobacco Control Studies

Walmart

Wolfson Institute of Preventive MedicineWorld Bank

World Health Organization (WHO)

Zenara


18/19

Page 54www.visiongain.com

Smoking Cessation Drugs: WorldMarket Prospects 2013-2023

Sublingual tablets.

Other NRT products are sold only at pharmacies and include the following:

Inhalers

Nasal spray.

In 2008, the Medicines and Healthcare products Regulatory Agency (MHRA) considered proposals

to end restricting sales of inhalers and nasal spray to pharmacies. This has led to availability of

these NRT products in other retail outlets, in addition to pharmacies.

4.4.1.3 The UK has Strong Anti-Smoking Legislation

A ban on smoking in public places in the UK lifted the UK smoking cessation market by 2009.

Currently, the UK is the largest European smoking cessation market and the second-largest in the

world. The UK Government has been active in discouraging smoking in recent years. Smoking

cessation products have been reimbursed by the NHS since 2001. In addition, since October 2007

it has become illegal in the UK to sell tobacco to people under the age of 18 (previously it was 16).

All forms of tobacco advertising have also been banned, and there is a virtual blanket ban on

smoking in all enclosed public spaces, such as offices and restaurants. All of these measures are

helping to reduce the prevalence of smoking in the UK, and visiongain expects this to, in turn,

provide a boost to the smoking cessation drug market in the UK over the forecast period.

4.4.1.4 UK Smoking Cessation Market, 2012

In 2012, the UK smoking cessation market was worth $177m, and this represents an increase of

1.31% over the previous years revenue figure of $174m

4.4.1.5 UK Smoking Cessation Market Forecast, 2013-2023The UK smoking-cessation market is the largest in Europe and the government has been vigorous

in introducing bans on smoking and promoting smoking cessation plans and products. Visiongain

therefore believes that the market for smoking cessation drugs market will grow moderately from

2013 to 2023. The UK Government's strong anti-smoking agenda, including its willingness to

reimburse smoking cessation products, will provide a strong impetus for smokers to stop smoking.

This will lead to increased sales of smoking cessation products, visiongain concludes.


19/19

Page 55www.visiongain.com

Smoking Cessation Drugs: WorldMarket Prospects 2013-2023

The general public in the UK is aware of the dangerous effects of smoking and the availability of

smoking cessation products. Visiongain predicts that the UK smoking cessation market will

therefore show increasing growth rate at a modest pace. Starting at a value of $179m in 2013, by

2017, the size of the UK market will have increased to $209m at a CAGR of 3.89%. Moreover, by

2023, the market size would have increased to $289m, at a CAGR of 4.89%.

2 01 1 2 01 2 2 01 3 2 01 4 2 01 5 2 01 6 2 01 7 2 01 8 2 01 9 2 02 0 2 02 1 2 02 2 2 02 3

UK ($m) 174 177 179 184 190 199 209 221 235 249 264 277 289

Annual Growth (%) 1.31 1.68 2.57 3.40 4.31 5.29 5.91 6.07 6.16 5.75 5.04 4.47

CAGR (%, from 2013) 3.89 4.89

4.4.2 The French Smoking Cessation Market

4.4.2.1 Tobacco Use in France is Still High

There are an estimated 15 million tobacco smokers in France, representing a national prevalence

of 29% among people aged 15 years or older (35% among men and 23% among women).

Smoking prevalence has remained fairly stable in the last five years and does not appear to have

been greatly affected by the ban on smoking in pubic places, which began on 1st January 2007.

0

50

100

150

200

250

300

350

2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

UK

Reve

nues($m)

Year

Source: visiongain 2013

Table 4.9 UK Smoking Cessation Market Forecast ($m), 2012-2023

Figure 4.7 UK Smoking Cessation Market Forecast ($m), 2012-2023

Source: visiongain 2013

smoking cessation drugs_world market prospects 2013-2023

Documents